Neisseria gonorrhoeae: Difference between revisions
From IDWiki
Neisseria gonorrhoeae
(→) |
(→: added citation) |
||
| Line 5: | Line 5: | ||
* Resistance |
* Resistance |
||
** About 50% resistance to [[fluoroquinolones]] |
** About 50% resistance to [[fluoroquinolones]] |
||
** Rates of MDR gonorrhea is increasing in Canada, mostly driven by [[azithromycin]] resistance |
** Rates of MDR gonorrhea is increasing in Canada, mostly driven by [[azithromycin]] resistance<ref>Multidrug-resistant and extensively drug-resistant gonorrhea in Canada, 2012–2016. ''CCDR''. 2019:45(2/3):45–53. https://doi.org/10.14745/ccdr.v45i23a01</ref> |
||
** XDR gonorrhea is still rare in Canada |
** XDR gonorrhea is still rare in Canada |
||
Revision as of 15:26, 27 August 2019
- Causes gonorrhea
Epidemiology
- Resistance
- About 50% resistance to fluoroquinolones
- Rates of MDR gonorrhea is increasing in Canada, mostly driven by azithromycin resistance[1]
- XDR gonorrhea is still rare in Canada
Clinical Presentation
Anorectal gonorrhea
- Often asymptomatic
- Can cause anorectal pain, discharge, and pruritis
- Anal intercourse not required, especially in women
Diagnosis
- Resistance
- MDR gonorrhea: resistance to one of azithromycin or a cephalosporin
- XDR if resistance to both azithromycin and a cephalosporin
- ↑ Multidrug-resistant and extensively drug-resistant gonorrhea in Canada, 2012–2016. CCDR. 2019:45(2/3):45–53. https://doi.org/10.14745/ccdr.v45i23a01
References
- ^ I Martin, P Sawatzky, V Allen, B Lefebvre, LMN Hoang, P Naidu, J Minion, P Van Caeseele, D Haldane, RR Gad, G Zahariadis, A Corriveau, G German, K Tomas, MR Mulvey. Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012–2016. Canada Communicable Disease Report. 2019;45(2/3):45-53. doi:10.14745/ccdr.v45i23a01.
